A phase 1 dose-escalating study for CT-P27 on its own and in combination with Tamiflu
Not Applicable
Active, not recruiting
- Conditions
- Diseases of th respiratory system
- Registration Number
- KCT0001617
- Lead Sponsor
- Celltrion
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
Healthy Male & Female volunteers
Exclusion Criteria
1. Subject has a medical condition of diseases including endocrine, cardiovascular, infection, cancer, or renal, neurological, and haematological disease.
2. History or presence of regular alcohol consumption
3. Subject in pregnancy or breastfeeding
4. Veins unsuitable for infusion and/or repeat venepuncture
5. Vulnerable subject
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety and tolerability of CT-P27
- Secondary Outcome Measures
Name Time Method Pharmacokinetics of CT-P27 components(CT-P22 and CT-P23);Safety and tolerability of CT-P27